Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

digital technology

- PMLiVE

AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer

Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually

- PMLiVE

AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies

Almost three billion people globally are thought to be either overweight or obese

- PMLiVE

AstraZeneca announces $15bn investment in Chinese manufacturing and R&D by 2030

The pharma company will be the first global biopharma with end-to-end cell therapy capabilities in China

- PMLiVE

AstraZeneca’s Saphnelo demonstrates positive results in systemic lupus erythematosus

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US

- PMLiVE

AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

Around one in five breast cancer cases are HER2-positive

Amiculum's Aaron Fletcher smiling to camera on the left, with text on the right that reads 'AI persona generation'

AI persona generation for healthcare: quick wins & real-world impact

By Aaron Fletcher

Amiculum

VuuAI and Amiculum

VuuAI and Amiculum partner to transform content engagement in pharma

Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation platform. The collaboration is designed to optimize the deployment of...

Amiculum

- PMLiVE

AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

In 2022, nearly one million new patients were diagnosed with gastric cancer

- PMLiVE

Does real-world use of AI in systematic literature reviews result in time and cost savings?

By Manca Povsic and Emma Griffiths

Amiculum

- PMLiVE

Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.

Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.

Inizio

- PMLiVE

AstraZeneca announces $2bn investment in US manufacturing

The new and expanded facilities will support production of rare disease drug treatments

- PMLiVE

AstraZeneca reports positive results from rare disease trial

HES is a group of rare disorders characterised by persistently elevated levels of white blood cells

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links